The US FDA has approved Pfizer's maternal RSV vaccine- Abrysvo

August 22, 2023: The vaccine, called Abrysvo, is given as a single injection during the middle of the third trimester of pregnancy. It is 82% effective in preventing severe RSV infection in infants from birth to six months old.

RSV is a common respiratory virus that can cause mild to severe illness in infants, young children, and adults with weakened immune systems. It is the leading cause of hospitalization for infants under one-year-old in the United States.

The approval of Abrysvo is a breakthrough in the fight against RSV. It is the first vaccine that can be used to protect infants from this potentially deadly virus. The vaccine will be available in the US in the coming months.

Here are some key takeaways from the news:

• The FDA has approved Pfizer’s maternal RSV vaccine to protect infants.
• The vaccine is given as a single injection during the middle of the third trimester of pregnancy.
• The vaccine is 82% effective in preventing severe RSV infection in infants from birth to six months old.
• RSV is a common respiratory virus that can cause mild to severe illness in infants, young children, and adults with weakened immune systems.
• The approval of Abrysvo is a breakthrough in the fight against RSV.
• If you are pregnant, talk to your doctor about whether Abrysvo suits you. The vaccine is safe and effective and can help protect your baby from RSV.